IMRA.OQ
Latest Trade
9.97USDChange
-2.34(-19.01%)Volume
102,775Today's Range
-
10.7552 Week Range
-
61.00As of on the NASDAQ ∙ Minimum 15 minute delay
Previous Close | 12.31 |
|---|---|
Open | 10.11 |
Volume | 102,775 |
3M AVG Volume | 2.80 |
Today's High | 10.75 |
Today's Low | 8.50 |
52 Week High | 61.00 |
52 Week Low | 8.50 |
Shares Out (MIL) | 17.41 |
Market Cap (MIL) | 173.55 |
Forward P/E | -2.60 |
Dividend (Yield %) | -- |
Imara Inc - Reported Results From Phase 2A Clinical Trial Of Imr-687 In Adult Patients With Sickle Cell Disease
Imara Presents IMR-687 Phase 2A Open Label Extension Case Reports On Two Patients With Sickle Cell Disease At 62nd Ash Annual Meeting And Exposition
Imara Reports Q3 Loss Per Share Of $0.72
Imara, Inc. is a clinical-stage biopharmaceutical company. The Company is developing and commercializing therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin. The Company’s product pipeline include IMR-687, which is an oral, once-a-day, potentially disease-modifying treatment for sickle cell disease (SCD), and beta-thalassemia. Its IMR-687 is a selective, small molecule inhibitor of phosphodiesterase-9 (PDE9). The Company is conducting a Phase 2a clinical trial of IMR-687 in adult patients with SCD and a Phase 2b clinical trial for the treatment of patients with beta-thalassemia.
Industry
Biotechnology & Drugs
Contact Info
116 HUNTINGTON AVENUE, 6TH FLOOR
BOSTON, MA
02116
United States
+1.617.2062020
https://imaratx.com/Executive Leadership
David M. Mott
Independent Chairman of the Board of Director
Rahul D. Ballal
President, Chief Executive Officer, Director
Michael P. Gray
Chief Financial Officer, Chief Operating Officer
Lynette Hopkinson
Senior Vice President - Regulatory
Edward R. Conner
Director
Price To Earnings (TTM) | -- |
|---|---|
Price To Sales (TTM) | -- |
Price To Book (MRQ) | 1.83 |
Price To Cash Flow (TTM) | -- |
Total Debt To Equity (MRQ) | 0.00 |
LT Debt To Equity (MRQ) | 0.00 |
Return on Investment (TTM) | -- |
Return on Equity (TTM) | -- |
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.